Published Manuscripts (2006)

Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. International Journal of Clinical Practice 2006; 60(9): 1138-45

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de ZD, Parving HH, Laville M. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Current Medical Research and Opinion 2006; 22(11): 2095-100

Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brandle M. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Medical Weekly 2006; 136(21): 346-52

Tucker DM, Palmer AJ, Valentine WJ, Roze S, Ray JA. Counting the costs of overweight and obesity: modeling clinical and cost outcomes. Current Medical Research and Opinion 2006; 22(3): 346-52

Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, Roze S. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Advances in Therapy 2006; 23(2): 191-207

Roze S, Valentine WJ, Evers T, Palmer AJ. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Current Medical Research and Opinion 2006; 22(7): 1415-24

Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, Mehin N, Gabriel S. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes and Metabolism 2006; 32(1): 69-76

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H. Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy. Deutsche Medizinische Wochenschrift 2006; 131(31): 1721-6

Close phone HUD
+41 61 271 6214
Dial with SkypeOutDial with SkypeOut
Close phone HUD
+41 79 340 4644
Dial with SkypeOutDial with SkypeOut